GSK shares fell more than 5% after U.S. health officials narrowed their recommendation of respiratory syncytial virus vaccines to a smaller age range and more at-risk patients.
Your email address will not be published. Required fields are marked *
Name *
Email *
Website
Save my name, email, and website in this browser for the next time I comment.
test account :